手术视频
关于我们
联系我们
中心官网
泌尿系统常见疾病循证医学证据
首页
良性前列腺增生
泌尿系统感染
泌尿系统结石
前列腺炎
前列腺癌
膀胱肿瘤
肾癌
其他
首页
搜索结果
证据分类
良性前列腺增生
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
手术视频
调查问卷
泌尿系统感染
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
泌尿系统结石
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
前列腺炎
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
前列腺癌
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
膀胱肿瘤
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
肾癌
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
其他
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
搜索结果
按关键字
按标题
按关键词
按摘要
按作者
按期刊
共搜索到
3条
与
MSD
有关的结果
The clinical efficacy and safety of equipment-assisted intravesical instillation of mitomycin C after transurethral resection of bladder tumour in patients with nonmuscular invasive bladder cancer: A meta-analysis
2022 年 发布于
Int J Urol
86 卷 第 1 期
Zhou W.
Liu J.
Mao D.
Hu C.
Gao D.
Antibodies
Monoclonal
Humanized/*therapeutic use
*Carcinoma
Transitional Cell/drug therapy
Humans
Prognosis
Retrospective Studies
*Urinary Bladder Neoplasms/drug therapy
Metastatic urothelial carcinoma
Pembrolizumab
Prognostic factor
Janssen
and Pfizer. Takahiro Kimura is a paid consultant/advisor of Astellas
Bayer
Janssen and Sanofi. Shahrokh F. Shariat is a paid as follows: Honoraria:
Astellas
AstraZeneca
Bayer
BMS
Cepheid
Ferring
Ipsen
Janssen
Lilly
MSD
Olympus
Pfizer
Pierre Fabre
Richard Wolf
Roche
Sanochemia
Sanofi
Takeda
Urogen. Consulting or Advisory Role: Astellas
AstraZeneca
Bayer
BMS
Cepheid
Ferring
Ipsen
Janssen
Lilly
MSD
Olympus
Pfizer
Pierre Fabre
Richard Wolf
Roche
Sanochemia
Sanofi
Takeda
Urogen. Speakers Bureau: Astellas
Astra
Zeneca
Bayer
BMS
Cepheid
Ferring
Ipsen
Janssen
Lilly
MSD
Olympus
Pfizer
Pierre Fabre
Richard Wolf
Roche
Sanochemia
Sanofi
Takeda
Urogen
Movember Foundation. The other authors declare no conflicts of interest
associated with this manuscript.
文献简介
原文链接
[Expert consensus of multi-disciplinary collaboration on bladder-preserving treatment for bladder cancer in China]
2022 年 发布于
Zhonghua Zhong Liu Za Zhi
44 卷 第 3 期
Urological Chinese Oncology Group
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
*Carcinoma
Transitional Cell/pathology
Cisplatin/therapeutic use
Cystectomy
Humans
Muscles/pathology
Neoadjuvant Therapy
Neoplasm Invasiveness
*Urinary Bladder Neoplasms/pathology
Bladder cancer
Muscle-invasive
Urothelial
from
MSD
and BMS and Speaker and Other from AstraZecena. BPV reports Advisory
Board
Speaker and Other from Astellas
Roche
BMS and Merk-Pfizer
Advisory
Board and Other from Ipsen
Advisory Board and Speaker from EUSA and
MSD
and
Advisory Board from Sanofi. IPF report Advisory Board
Speaker and Other from
Pfizer
Speaker and Other from Ipsen and Roche
Advisory Board from EUSA and BMS
and Speaker from Novartis and
MSD
. OFC reports Advisory Board and Speaker from
Ipsen and Astellas
Advisory Board from BMS and Pfizer-Merck and Speaker from
AstraZeneca. AGA has received research funding from Astellas
travel grants from
Astellas
Jansen
Sanofi
BMS
Roche
Pfizer and Ipsen and honoraria for speaker
engagements
advisory boards and continuous medical education from Janssen
Astellas
Sanofi
Bayer
Roche
Ipsen
BMS
MSD
Pfizer
Eusa Pharma
Eisai and
AstraZeneca. JAA reports honoraria from Astellas
Pfizer and BMS
conulting or
advisory role from Pfizer
Astellas
Janssen-Cilag
MSD
Oncology
BMS
Merck
AstraZeneca
Bayer and Eisai and Research Funding from BMS. RMB
SVE
CCD and MDS
have nothing to disclose.
文献简介
原文链接
吉西他滨较丝裂霉素治疗 TURBT 后非肌层浸润性膀胱癌的复发率低、毒副作用小 : 基于随机对照试验的荟萃分析
2021 年 发布于
PeerJ
60 卷 第 5 期
彭磊
蒙春杨
李金泽
李云祥
李进铭
赵攀
韦堂墙
伍季
Adult
Aged
Aged
80 and over
Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
B7-H1 Antigen/antagonists & inhibitors
Carcinoma/*drug therapy/immunology/mortality/pathology
Clinical Decision-Making
Female
Humans
Immune Checkpoint Inhibitors/adverse effects/*therapeutic use
Male
Middle Aged
Patient Selection
Progression-Free Survival
Time Factors
Urinary Bladder Neoplasms/*drug therapy/immunology/mortality/pathology
Urothelium/*drug effects/immunology/pathology
Immune-checkpoint inhibitor
Meta-analysis
Programmed death-ligand 1
Urothelial carcinoma
interests/personal relationships which may be considered as potential competing
interests: The authors certify that all conflicts of interest
including specific
financial interests and relationships and affiliations relevant to the subject
matter or materials
discussed in the article are listed as follows: Shahrokh
Shariat owns or co-owns the following patents: methods to determine prognosis
after therapy for prostate cancer. Granted 2002-09-06. Methods to determine
prognosis after therapy for bladder cancer. Granted 2003-06-19. Prognostic
methods for patients with prostatic disease. Granted 2004-08-05. Soluble Fas:
urinary marker for the detection of bladder transitional cell carcinoma. Granted
2010-07-20. He has a consulting or advisory role for the following: Astellas
Astra Zeneca
Bayer
BMS
Cepheid
Ferring
Ipsen
Jansen
Lilly
MSD
Olympus
Pfizer
Pierre Fabre
Roche
Sanochemia
Sanofi
Takeda
Urogen and Wolff. All
remaining authors have declared no conflicts of interest.
文献简介
原文链接